nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.36485/1561-6274-2024-28-4-39-44RBQJHZnefr-2350Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESОсобенности поражения почек при системной красной волчанкеFeatures of kidney damage in systemic lupus erythematosushttps://orcid.org/0000-0001-6863-6898КуницкаяН. А.KunitskayaN. A.

Проф. Куницкая Наталия Александровна, д-р мед. наук, кафедра внутренних болезней, нефрологии, общей и клинической фармакологии с курсом фармации

191015, Санкт-Петербург, Пискаревский пр., д. 47

Prof. Kunitskaya А. Natalia, MD, PhD, Department of Internal Medicine, Nephrology, General and Clinical Pharmacology with Pharmacy course

191015, Russia, Saint Petersburg, Piskarevsky, 47

 

scvssd@yandex.ruhttps://orcid.org/0000-0003-2704-679XКулаеваН. Н.KulaevaN. N.

Доц. Кулаева Наталия Николаевна, канд. мед. наук, кафедра внутренних болезней, нефрологии, общей и клинической фармакологии с курсом фармации

191015, Санкт-Петербург, Пискаревский пр., д. 47

Associate prof. Kulaeva N. Nikolaevna, MD, PhD, Department of Internal Medicine, Nephrology, General and Clinical Pharmacology with Pharmacy course

191015, Russia, Saint Petersburg, Piskarevsky, 47

 

kulaevanat@mail.ruhttps://orcid.org/0009-0001-2337-7906КуницкийМ. А.KunitskyM. A.

Студент Куницкий Матвей Александрович, кафедра внутренних болезней, нефрологии, общей и клинической фармакологии с курсом фармации

191015, Санкт-Петербург, Пискаревский пр., д. 47

Student Kunitsky Matvey Alexandrovich, Department of Internal Medicine, Nephrology, General and Clinical Pharmacology with Pharmacy course

191015, Russia, Saint Petersburg, Piskarevsky, 47

Северо-Западный государственный медицинский университет имени И.И. МечниковаРоссияI.I. Mechnikov Northwestern State Medical UniversityRussian Federation2024160120252843944Copyright © Куницкая Н.А., Кулаева Н.Н., Куницкий М.А., 20252025Куницкая Н.А., Кулаева Н.Н., Куницкий М.А.Kunitskaya N.A., Kulaeva N.N., Kunitsky M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/2350

Нарушение функции почек характерно для системной красной волчанки (СКВ) и других аутоиммунных заболеваний. В настоящее время, учитывая доступность многих диагностических манипуляций и возможности этиопатогенетического лечения, ревматологам и нефрологам необходимо своевременно заподозрить наличие заболевания почек у пациентов с СКВ и принять необходимые меры по диагностике и лечению. Современные стратегии классификации и лечения СКВ скорректированы с учетом результатов биопсии почек, что значительно улучшило прогноз при этом заболевании. С другой стороны – необходимо помнить, что длительное использование иммунодепрессантов, а также сопутствующие заболевания, такие как сахарный диабет, артериальная гипертензия и сердечно-сосудистые осложнения, могут являться основными причинами поражения почек у пациентов с СКВ. В данном обзоре проанализированы нарушения функции почек вследствие основного заболевания, побочных эффектов препаратов и принятии решений о своевременном соответствующем лечении.

Impaired renal function is characteristic of systemic lupus erythematosus (SLE) and other autoimmune diseases. Given the availability of various diagnostic methods and the potential for etiopathogenetic treatment, it is crucial for rheumatologists and nephrologists to promptly suspect kidney disease in patients with SLE and take necessary measures for diagnosis and treatment. Modern strategies for classifying and treating SLE guidelines have been updated to incorporate findings from kidney biopsies., significantly improving the prognosis for this disease. On the other hand, it should be remembered that long-term use of immunosuppressants, as well as concomitant diseases such as diabetes mellitus, hypertension, and cardiovascular complications, might be the main causes of kidney damage in patients with SLE. In this review, we discuss renal dysfunction due to underlying diseases, the side effects of medications, and the importance of making timely decisions.

поражение почексистемные заболевания соединительной тканисистемная красная волчанкаkidney damagesystemic connective tissue diseasessystemic lupus erythematosusReferencesAnders HJ, Vielhauer V. Renal comorbidity in patients with rheumatic disease. Arthritis Res Ther 2021 Jun 29;13(3):222. doi: 10.1186/ar3256Anders HJ, Vielhauer V. Renal co-morbidity in patients with rheumatic disease. Arthritis Res Ther 2021 Jun 29;13(3):222. doi: 10.1186/ar3256Dolgih SV, Vorobieva OA, Mazurov VI. The specialties of the renal damage in connective tissue diseases and systemic vasculitis (literature review). Nefrologia 2009;13(2):35–41. doi: 10.24884/1561-6274-2009-13-2-35-41Dolgih SV, Vorobieva OA, Mazurov VI. The specialties of the renal damage in connective tissue diseases and systemic vasculitis (literature review). Nefrologia 2009;13(2):35–41. doi: 10.24884/1561-6274-2009-13-2-35-41Goilav B, Putterman C. The Role of Anti-DNA Antibodies in the Development of Lupus Nephritis: An alternative, or complementary, viewpoint? Semin Nephrol 2015 Sep;35(5):439–443. doi: 10.1016/j.semnephrol.2015.08.005Goilav B, Putterman C. The Role of Anti-DNA Antibodies in the Development of Lupus Nephritis: An alternative, or complementary, viewpoint? Semin Nephrol 2015 Sep;35(5):439–443. doi: 10.1016/j.semnephrol.2015.08.005Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010 Dec;21(12):2028–2035. doi: 10.1681/ASN.2010050472Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010 Dec;21(12):2028–2035. doi: 10.1681/ASN.2010050472Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 2023 Aug;65(8):2154–2160. doi: 10.1002/art.38006Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 2023 Aug;65(8):2154–2160. doi: 10.1002/art.38006Hoover PJ, Costenbader KH. Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective. Kidney Int 2016 Sep;90(3):487–492. doi: 10.1016/j.kint.2016.03.042Hoover PJ, Costenbader KH. Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective. Kidney Int 2016 Sep;90(3):487–492. doi: 10.1016/j.kint.2016.03.042Dall’Era M. Treatment of lupus nephritis: current paradigms and emerging strategies. Curr Opin Rheumatol 2017 May;29(3):241–247. doi: 10.1097/BOR.0000000000000381Dall’Era M. Treatment of lupus nephritis: current paradigms and emerging strategies. Curr Opin Rheumatol 2017 May;29(3):241–247. doi: 10.1097/BOR.0000000000000381Golovach IYu. Lupus nephritis: a modern treatment paradigm. Kidneys 2018;7(2):122–131. doi: 10.22141/23071257.7.2.2018.127399Golovach IYu. Lupus nephritis: a modern treatment paradigm. Kidneys 2018;7(2):122–131. doi: 10.22141/23071257.7.2.2018.127399Krasnova TN. Renal involvement in systemic lupus erythematosus: the present views of its pathogenesis and clinical manifestations and the approaches to its treatment. Modern Rheumatology 2018; 3: 18–21. doi: 10.14412/1996-7012-2008483. (In Russian)Krasnova TN. Renal involvement in systemic lupus erythematosus: the present views of its pathogenesis and clinical manifestations and the approaches to its treatment. Modern Rheumatology 2018; 3: 18–21. doi: 10.14412/1996-7012-2008483. (In Russian)Espeli M, Bokers S, Giannico G et al. Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol 2011 Feb;22(2):296–305. doi: 10.1681/ASN.2010050515Espeli M, Bokers S, Giannico G et al. Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol 2011 Feb;22(2):296–305. doi: 10.1681/ASN.2010050515Aggarwal R, Sestak AL, D'Sousa A, Dillon SP, Namjou B, Scofield RH. Complete complement deficiency in a large cohort of familial systemic lupus erythematosus. Lupus 2020 Jan;19(1):52– 57. doi: 10.1177/0961203309346508Aggarwal R, Sestak AL, D'Sousa A, Dillon SP, Namjou B, Scofield RH. Complete complement deficiency in a large cohort of familial systemic lupus erythematosus. Lupus 2020 Jan;19(1):52– 57. doi: 10.1177/0961203309346508Birmingham DJ, Irshaid F, Nagaraja HN et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 2020 Oct;19(11):1272–1280. doi: 10.1177/0961203310371154Birmingham DJ, Irshaid F, Nagaraja HN et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 2020 Oct;19(11):1272–1280. doi: 10.1177/0961203310371154Oelzner P, Deliyska B, Funfstuck R, Hein G, Herrmann D, Stein G. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus – relationship with disease activity and renal involvement. Clin Rheumatol 2003 Oct;22(4–5):271– 278. doi: 10.1007/s10067-003-0724-3Oelzner P, Deliyska B, Funfstuck R, Hein G, Herrmann D, Stein G. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus – relationship with disease activity and renal involvement. Clin Rheumatol 2003 Oct;22(4–5):271– 278. doi: 10.1007/s10067-003-0724-3Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 2011 Oct;20(12):1267– 1274. doi: 10.1177/0961203311411597Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 2011 Oct;20(12):1267– 1274. doi: 10.1177/0961203311411597Stokes MB, D'Agati VD. Full-house glomerular deposits: beware the sheep in wolf's clothing. Kidney Int 2018 Jan;93(1):18– 20. doi: 10.1016/j.kint.2017.08.001Stokes MB, D'Agati VD. Full-house glomerular deposits: beware the sheep in wolf's clothing. Kidney Int 2018 Jan;93(1):18– 20. doi: 10.1016/j.kint.2017.08.001Hahn BH, McMahon MA, Wilkinson A et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012 Jun;64(6):797–808. doi: 10.1002/acr.21664Hahn BH, McMahon MA, Wilkinson A et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012 Jun;64(6):797–808. doi: 10.1002/acr.21664Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004 Feb;15(2):241–250Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004 Feb;15(2):241–250KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2021;100(4S):S1–S276KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2021;100(4S):S1–S276Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10year follow-up data of the euro-lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2020 Jan;69(1):61–64. doi: 10.1136/ard.2008.102533Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10year follow-up data of the euro-lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2020 Jan;69(1):61–64. doi: 10.1136/ard.2008.102533Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009 May;20(5):1103–1112. doi: 10.1681/ASN.2008101028Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009 May;20(5):1103–1112. doi: 10.1681/ASN.2008101028Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010 Jan;77(2):152–160. doi: 10.1038/ki.2009.412Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010 Jan;77(2):152–160. doi: 10.1038/ki.2009.412Kalloo S, Aggarwal N, Mohan P, Radhakrishnan J. Lupus nephritis: treatment of resistant disease. Clin J Am Soc Nephrol 2013 Jan;8(1):154–161. doi: 10.2215/CJN.05870612Kalloo S, Aggarwal N, Mohan P, Radhakrishnan J. Lupus nephritis: treatment of resistant disease. Clin J Am Soc Nephrol 2013 Jan;8(1):154–161. doi: 10.2215/CJN.05870612Illei GG, Cervera R, Burt RK et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis 2021 Dec;70(12):2071–2074. doi: 10.1136/ard.2010.148049Illei GG, Cervera R, Burt RK et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis 2021 Dec;70(12):2071–2074. doi: 10.1136/ard.2010.148049Stummvoll GH, Schmaldienst S, Smolen JS, Derfler K, Biesenbach P. Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity. Nephrol Dial Transplant 2012 Feb;27(2):618–26. doi: 10.1093/ndt/gfr239Stummvoll GH, Schmaldienst S, Smolen JS, Derfler K, Biesenbach P. Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity. Nephrol Dial Transplant 2012 Feb;27(2):618–26. doi: 10.1093/ndt/gfr239Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol. 2005 Apr;66(4):395–402. doi: 10.1016/j.humimm.2005.01.022Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol. 2005 Apr;66(4):395–402. doi: 10.1016/j.humimm.2005.01.022Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 2011 Feb;127(2):303–312; quiz 313-4. doi: 10.1016/j.jaci.2010.12.1087Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 2011 Feb;127(2):303–312; quiz 313-4. doi: 10.1016/j.jaci.2010.12.1087Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2015;14 Suppl 1:s33-38Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2015;14 Suppl 1:s33-38Lu TY, Ng KP, Cambridge G et al. A retrospective sevenyear analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college London hospital: the first fifty patients. Arthritis Rheum 2019 Apr 15;61(4):482–487. doi: 10.1002/art.24341Lu TY, Ng KP, Cambridge G et al. A retrospective sevenyear analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college London hospital: the first fifty patients. Arthritis Rheum 2019 Apr 15;61(4):482–487. doi: 10.1002/art.24341Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010 Jan;62(1):222–233. doi: 10.1002/art.27233Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010 Jan;62(1):222–233. doi: 10.1002/art.27233Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum 2012 Apr;64(4):1215–1226. doi: 10.1002/art.34359Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum 2012 Apr;64(4):1215–1226. doi: 10.1002/art.34359Tony HP, Burmester G, Schulze-Koops H et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011 May 13;13(3):R75. doi: 10.1186/ar3337Tony HP, Burmester G, Schulze-Koops H et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011 May 13;13(3):R75. doi: 10.1186/ar3337Berntsson SG, Katsarogiannis E, Lourenço F, MoraesFontes MF. Progressive Multifocal Leukoencephalopathy and Systemic Lupus Erythematosus: Focus on Etiology. Case Rep Neurol 2016 Mar 16;8(1):59–65. doi: 10.1159/000444874Berntsson SG, Katsarogiannis E, Lourenço F, MoraesFontes MF. Progressive Multifocal Leukoencephalopathy and Systemic Lupus Erythematosus: Focus on Etiology. Case Rep Neurol 2016 Mar 16;8(1):59–65. doi: 10.1159/000444874Condon MB, Ashby D, Pepper RJ et al. Prospective observational singlecentre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013 Aug;72(8):1280–1286. doi: 10.1136/annrheumdis-2012-202844Condon MB, Ashby D, Pepper RJ et al. Prospective observational singlecentre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013 Aug;72(8):1280–1286. doi: 10.1136/annrheumdis-2012-202844Petri M, Stohl W, Chatham W et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2021 Aug;58(8):2453–2459. doi: 10.1002/art.23678Petri M, Stohl W, Chatham W et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2021 Aug;58(8):2453–2459. doi: 10.1002/art.23678Wallace DJ, Stohl W, Furie RA et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2019 Sep 15;61(9):1168–1178. doi: 10.1002/art.24699Wallace DJ, Stohl W, Furie RA et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2019 Sep 15;61(9):1168–1178. doi: 10.1002/art.24699Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011 Feb 26;377(9767):721–731. doi: 10.1016/S01406736(10)61354-2Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011 Feb 26;377(9767):721–731. doi: 10.1016/S01406736(10)61354-2Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011 Dec;63(12):3918–3930. doi: 10.1002/art.30613Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011 Dec;63(12):3918–3930. doi: 10.1002/art.30613Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8(3):R74. doi:10.1186/ar1942Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8(3):R74. doi:10.1186/ ar1942Dillon SR, Harder B, Lewis KB et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 2021;12(2):R48. doi: 10.1186/ar2959Dillon SR, Harder B, Lewis KB et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 2021;12(2):R48. doi: 10.1186/ar2959

The authors declare that there are no conflicts of interest present.